Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
19,58 USD | -2,71% | -7,99% | -35,82% |
08/08 | La perdita netta Q2 di Intellia Therapeutics si allarga, il fatturato cala | MT |
08/08 | Transcript : Intellia Therapeutics, Inc., Q2 2024 Earnings Call, Aug 08, 2024 |
Aggiungi a un elenco 0 selezionato | P/E ratio | Price to Book | PEG | EV/Fatturato | EV / EBITDA | EV / EBIT | Rendimento (Y) | Capi. ($) | |
---|---|---|---|---|---|---|---|---|---|
-3.71x | 2,555 | -166.24x | 24.77x | -2.47x | -2.57x | -.--% | 2,04 Mrd | ||
47.72x | 4,097 | 1.64x | 6.34x | 22.29x | 34.27x | +0.84% | 46,68 Mrd | ||
30.53x | 6,128 | 5.37x | 3.53x | 14.68x | 17.35x | -.--% | 42,88 Mrd | ||
-105.75x | 123,19 | 3.39x | 14.2x | -242.98x | -178.64x | -.--% | 32,89 Mrd | ||
-8.63x | 2,899 | 0.34x | 7.26x | -6.84x | -6.06x | -.--% | 30,47 Mrd | ||
75.98x | 2,401 | -2.42x | 11.59x | 40.03x | 63.59x | +0.26% | 30,1 Mrd | ||
30.33x | 2,311 | 1.22x | 3x | 13.89x | 14.95x | -.--% | 23,23 Mrd | ||
13.84x | 2,049 | 0.55x | 4.56x | 8.89x | 9.19x | -.--% | 15,24 Mrd | ||
61.41x | 5,016 | 4.26x | 9.53x | 27.2x | 30.15x | +0.43% | 11,7 Mrd | ||
50.76x | 2,750 | -1.3x | 5.32x | 14.33x | 18.66x | -.--% | 10,2 Mrd | ||
28.29x | 10,65 | 0.93x | 4.4x | 21.13x | 22.71x | -.--% | 10,14 Mrd | ||
30.2x | 2,474 | -0.95x | 2.96x | 11.89x | 14.94x | -.--% | 9,81 Mrd | ||
-12x | 4,506 | 1.19x | 3482.26x | -8.82x | -8.7x | -.--% | 6,95 Mrd | ||
48.89x | 4,121 | 15.53x | 8.99x | 31.35x | 44.65x | +1.14% | 6,7 Mrd | ||
-11.52x | 9 590,50 | -0.26x | 8.99x | -11x | -10.47x | -.--% | 6,2 Mrd | ||
24.71x | 1,896 | -1.6x | 4.35x | 18.42x | 19.23x | +0.79% | 5,48 Mrd | ||
-69.02x | 73,50 | 0.81x | 9.42x | -20.59x | -20.55x | -.--% | 5,45 Mrd | ||
20.36x | 2,545 | 2.29x | 2.78x | 11.85x | 18.84x | +1.04% | 4,49 Mrd | ||
Media | 14,02x | 546,87 | -7,52x | 200,79x | -3,15x | 4,53x | +0,25% | 16,7 Mrd | |
Media ponderata per Capi. | 16,07x | 215,86 | 0,68x | 87,58x | -13,15x | -0,50x | +0,23% |
- Borsa valori
- Azioni
- Azione NTLA
- Settore Intellia Therapeutics, Inc.
- Valutazioni del settore
MarketScreener is also available in this country: United States.
Switch edition